---
title: Targeting Factor XI and Factor XIa to Prevent Thrombosis
date: '2023-12-24'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/38142404/?utm_source=curl&utm_medium=rss&utm_campaign=journals&utm_content=7603509&fc=None&ff=20231225170640&v=2.18.0
source: Blood
description: Direct oral anticoagulants (DOACs) that inhibit the coagulation proteases
  thrombin or factor Xa have replaced warfarin and other vitamin K antagonists (VKA)
  for most indications requiring long-term anticoagulation. In many clinical situations,
  DOACs are as effective as VKAs, cause less bleeding, and do not require laboratory
  monitoring. However, because DOACs target proteases that are required for hemostasis,
  their use increases the risk of serious bleeding. Concerns over ...
disable_comments: true
---
Direct oral anticoagulants (DOACs) that inhibit the coagulation proteases thrombin or factor Xa have replaced warfarin and other vitamin K antagonists (VKA) for most indications requiring long-term anticoagulation. In many clinical situations, DOACs are as effective as VKAs, cause less bleeding, and do not require laboratory monitoring. However, because DOACs target proteases that are required for hemostasis, their use increases the risk of serious bleeding. Concerns over ...